Effects of lovastatin on cortical excitability, E/I balance, and antioxidant markers in a case series of patients with drug-resistant epilepsy: a proof-of-concept study.

BACKGROUND: Drug-resistant epilepsy (DRE) remains a major clinical challenge, with neuroinflammation and excitatory/inhibitory (E/I) imbalance being implicated in its pathophysiology. This proof-of-concept case series aimed to investigate the neurochemical and neurophysiological effects of a short course of lovastatin in individuals with DRE. METHODS: Five participants with drug-resistant temporal lobe epilepsy completed a double-blind, placebo-controlled, crossover protocol involving oral administration of lovastatin (60 mg/day) and placebo for three consecutive days. Post-intervention assessments included: (1) magnetic resonance spectroscopy (MRS) in the visual cortex to quantify gamma-aminobutyric acid (GABA+), Glutamate (Glx), and Glutathione (GSH); (2) resting-state electroencephalogram (EEG) to measure the frequency of interictal epileptiform discharges (IEDs); and (3) event-related potentials (ERPs) during a facial recognition task. RESULTS: Compared to placebo, lovastatin administration was associated with a statistically significant reduction in the GABA+/Glx ratio (p = 0.041) and IED frequency (p = 0.04), alongside a statistically significant increase in GSH concentration (p = 0.039). Lovastatin also modulated visual processing ERPs, statistically significantly delaying the P100 latency (p = 0.04) and reducing the absolute N170 peak amplitude (p = 0.04). CONCLUSION: This study demonstrates that a short course of lovastatin can modulate key in vivo biomarkers of E/I balance, redox state, and cortical excitability in patients with DRE. These preliminary findings provide a mechanistic rationale for further, larger studies to explore the potential of statins as a novel strategy for modifying pathological brain activity.